$1.35
▼ -0.7% Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen Doses First Patient in Trial of Potential Eye Disease Drug
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Overview
52-week range
$1.01
$2.73
20% of range
Avg surprise (last 3)
+4.4%
Avg reaction (last 2)
-11.1%
0% positive
Latest IV / EM
235%
EM ±36.8% · $2 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.07 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-0.06 | $-0.05 | -20.0% | -20.0% | -19.5% | earnings |
| Fri Aug 1, 2025 | Jun/2025 | $-0.05 | $-0.06 | +16.7% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.05 | $-0.06 | +16.7% | — | -2.8% | earnings |
| Sun Jun 30, 2024 | Jun 2024 | $-0.04 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.05 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.10 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.08 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $2M | — | $2M | $1M | $1M | — | $1M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-16M | $-18M | — | $-18M | $-14M | $-15M | — | $-13M |
| Net income | $-25M | $-19M | — | $-20M | $-15M | $-15M | — | $-13M |
| EPS (diluted) | $-0.07 | $-0.06 | — | — | $-0.05 | $-0.05 | — | — |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $100M | $32M | $19M | $33M | $27M | $38M | — | $39M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $107M | $39M | $24M | $38M | $33M | $44M | $62M | $41M |
| Total assets | $124M | $57M | $44M | $58M | $54M | $64M | $82M | $62M |
| Long-term debt | $2M | $24M | $28M | $28M | $28M | $28M | $27M | $2M |
| Total liabilities | $141M | $51M | $56M | $54M | $51M | $49M | $53M | $21M |
| Total equity | $-17M | $6M | $-12M | $4M | $3M | $16M | $30M | $41M |